Insmed Incorporated (0JAV.L) • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0JAV.L in your mock portfolio yet.
Insmed is currently unprofitable, with a negative EPS of -5.75 and a correspondingly negative PE ratio, indicating ongoing losses rather than earnings-driven valuation. This profile is typical of a development-stage or growth-focused biotech that is investing heavily ahead of potential future revenue, but it also raises execution and financing risk. Without visibility into a clear path to profitability, the current fundamentals lean negative from a pure financial perspective.
Despite a recent 8.6% pullback over the past month, the stock trades dramatically above its 200-day moving average ($100.03 vs. $24.95), indicating a powerful longer-term uptrend. Such a large premium to the 200-day average typically reflects strong positive sentiment and momentum, even if it also raises the risk of volatility and corrections. The recent decline looks more like a consolidation within a strong uptrend than a confirmed reversal, based on the limited data provided.
Web traffic of about 61,155 monthly visitors is modest and the social media base is relatively small across Twitter/X, Instagram, and YouTube, with only slow growth in followers. LinkedIn stands out with 77,594 followers, suggesting stronger professional and industry visibility than retail or consumer-facing engagement. Overall, alternative data do not show a strong acceleration or deterioration in interest, pointing to a largely stable but unexciting digital footprint.
Insmed’s stock appears to be in a strong longer-term uptrend, trading far above its 200-day moving average despite a recent 8.6% pullback, which keeps the technical picture skewed bullish. However, the company remains unprofitable with a negative EPS and PE ratio, and alternative data show only modest, stable interest rather than surging engagement. Balancing strong technical momentum against weak current profitability and middling alternative data signals leads to an overall neutral stance, with the stock heavily dependent on future execution and news flow.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started